Nafarelin vs Buserelin — Peptide Comparison

Nafarelin vs Buserelin — Peptide Comparison Nafarelin vs Buserelin — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Nafarelin As prescribed–As prescribed mg Buserelin 200 mcg–1,500 mcg mcg Frequency Once daily Administration As directed by healthcare provider Subcutaneous injection Cycle Length Ongoing/indefinite Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Efficacy Endometriosis Treatment Precocious Puberty Hormone Regulation Hormone Suppression Cancer Management Fertility Support Technical Data Molecular Formula C66H83N17O13 Molecular Weight 1322.5 g/mol Half-Life Approximately 2-6 hours (varies by route of administration) Bioavailability ~2-3% (intranasal) CAS Number 86220-42-0 C60H86N16O13 1239.4 g/mol 2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days) ~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous) 57773-65-6 Protocols standard 400 mcg/day (one 200 mcg spray each nostril, AM and PM) Twice daily 6 months FDA-labeled endometriosis dose; start between cycle days 2-4. May increase to 800 mcg/day if amenorrhea is not achieved after 2 months [6]. advanced 1600-1800 mcg/day (400 mcg per nostril dosing) Twice daily (up to 3 times) Until resumption of puberty is desired FDA-labeled central precocious puberty dose: 1600 mcg/day standard, increasable to 1800 mcg/day [6]. starting 500 mcg Every 8 hours (3 times daily) First 7 days The product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5]. 200 mcg Ongoing maintenance After the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5]. 400 mcg (2 sprays per nostril) 3 times daily (1,200 mcg/day) The nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5]. 6.3 mg Once every 2 months Long-term A long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5]. 9.45 mg Once every 3 months A larger implant lasts about 3 months between placements [5]. Applications Managing moderate to severe endometriosis pain that doesn't respond to other treatments Nafarelin is particularly well-suited for individuals focused on managing moderate to severe endometriosis pain that doesn't respond to other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treating children with precocious puberty (early puberty) Nafarelin is particularly well-suited for individuals focused on treating children with precocious puberty (early puberty). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Preparing women for endometriosis surgery by reducing inflammation Nafarelin is particularly well-suited for individuals focused on preparing women for endometriosis surgery by reducing inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Improving fertility outcomes in assisted reproductive procedures Nafarelin is particularly well-suited for individuals focused on improving fertility outcomes in assisted reproductive procedures. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Managing advanced prostate cancer Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treating endometriosis and reducing associated pain Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Optimizing ovarian response during fertility treatments Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Hot flashes and night sweats (happen in 90% of users) Mood changes including depression or anxiety Decreased sexual interest Vaginal dryness Headaches Nasal irritation (if using spray formulation) Breast tenderness Muscle aches and joint pain Weight gain or changes in body composition Nausea and upset stomach Sleep problems Emotional sensitivity and mood swings Allergic reactions (rare) Significant bone density loss with extended use Severe mood disorders requiring medical attention Hot flashes (flushes of heat and redness) Night sweats and chills Vaginal dryness and discomfort Mood depression or anxiety Changes in sexual desire Weight changes Muscle and joint aches Nasal irritation or sinus problems Breast tenderness or swelling Acne Sleep disturbances Nausea Fatigue Bone pain Serious Severe allergic reaction Research Status FDA Status FDA approved for this use Safety Overview Nafarelin is FDA-approved with a well-established safety profile across decades of clinical use for endometriosis and precocious puberty. The most significant safety consideration is hypogonadism and bone density loss during prolonged therapy, requiring add-back therapy (norethindrone 0.4 mg daily) after 6 months to prevent osteoporosis. Common side effects—hot flashes, vaginal dryness, mood changes—are reversible upon discontinuation and typically diminish with continued use. Contraindications xPregnancy (can harm fetus - must use non-hormonal birth control) xHypersensitivity to GnRH agonists xUndiagnosed vaginal bleeding xSevere osteoporosis or bone disease FDA approved for other use Buserelin is an FDA-approved GnRH agonist with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users. xPregnancy or breastfeeding xCertain bone diseases when long-term use is planned Decision Guide Choose Nafarelin if... Managing moderate to severe endometriosis pain that doesn't respond to other treatments Treating children with precocious puberty (early puberty) Preparing women for endometriosis surgery by reducing inflammation Improving fertility outcomes in assisted reproductive procedures Choose Buserelin if... Managing advanced prostate cancer Treating endometriosis and reducing associated pain Optimizing ovarian response during fertility treatments